Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

May 13, 2025

Study Completion Date

May 20, 2025

Conditions

Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Bazedoxifene Acetate

40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules

Trial Locations (1)

Weill Institute for Neurosciences, University of California, San Francisco, San Francisco

All Listed Sponsors

lead

Riley Bove, MD

OTHER

NCT04002934 - Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis | Biotech Hunter | Biotech Hunter